Participated · Equity · Jul 2026

Xeltis develops implantable vascular and cardiovascular devices based on its Restorex® platform, which uses an advanced polymer implant that transforms into the patient’s own tissue and is gradually absorbed. Its lead product, aXess™, is an implantable blood vessel for hemodialysis vascular access that has received CE Mark approval and is being commercially deployed in Europe. The company is enrolling a US pivotal trial of aXess™ (now >50% enrolled) and is preparing for FDA submission and a US market launch. Xeltis plans to use recent funding to support European commercial rollout, upscale manufacturing and advance its XABG and XPAD clinical programs. Financially, the company raised €50m in 2025 from the European Investment Bank and existing shareholders and added €20.5m in 2026 from new and existing investors to fund its next phase of clinical, regulatory and commercial execution.

Participated · Series D · Sep 2024

eGenesis is a biotechnology company developing human-compatible engineered organs to address the global organ shortage. Its lead product candidate, the donor kidney EGEN-2784, carries three classes of genome edits: knockout of glycan-antigen synthesis genes, insertion of seven human transgenes to modulate rejection pathways, and inactivation of endogenous porcine retroviruses. The company’s EGEN genome engineering and production platform aims to comprehensively address cross-species molecular incompatibilities and viral risk. Proceeds from the $191 million Series D will be used to advance EGEN-2784 to a first-in-human kidney transplant study, advance pipeline programs (including acute liver failure and heart transplant), and scale production. In March 2024 eGenesis announced the world’s first successful porcine kidney transplant in a living patient under an FDA Expanded Access authorization, performed at Massachusetts General Hospital. The company says it is the only firm developing organs that carry all three classes of edits to address organ safety and efficacy. eGenesis develops human-compatible organs, tissues, and cells using gene-editing and genome-engineering to address barriers to xenotransplantation. The company harnesses gene editing technologies to make organs safe and effective for patients in need. Its development pipeline includes lead programs for kidney and islet cell transplants and earlier-stage programs targeting other solid organs. eGenesis intends to use its Series C proceeds to bring lead kidney and islet programs into human proof-of-concept studies, continue development of its proprietary gene-editing platform, and scale GMP production. The company is led by Paul Sekhri, President and Chief Executive Officer. Financially, eGenesis completed a $125m Series C financing in February 2021. eGenesis develops human-compatible organs using gene editing technologies such as CRISPR to overcome virology and immunology hurdles that have impeded xenotransplantation. The company is advancing an initial kidney product toward the clinic while pursuing programs in islet cell, liver, heart, and lung. It intends to use new funding to accelerate its kidney xenotransplant program into the clinic and to support advancement of other xenotransplant programs. eGenesis positions xenotransplantation as a potential solution for a broader organ recipient population and to expand applicability into areas such as cell therapy. The company is led by president and CEO Paul Sekhri and is based in Cambridge, Massachusetts. eGenesis completed a $100M Series B financing to support these efforts. eGenesis uses a CRISPR-based genome editing platform to engineer pig cells and organs intended for safe and effective human transplantation. The company’s core approach includes genomic engineering of pig cells, organ maturation, and eventual organ transplantation. eGenesis positions xenotransplantation as a solution to the severe shortage of transplantable human organs and aims to make it a routine lifesaving medical procedure. Its scientific team includes co-founder and CSO Luhan Yang and Harvard geneticist George Church, plus multiple scientists from Harvard with expertise in genome editing, synthetic biology, and transgenic animals. The company is in early stages of development and is advancing its platform toward delivering transplantable cells, tissues and organs. eGenesis announced a recent financing to support these development efforts.

Participated · Series F · Oct 2013

CVRx develops the BAROSTIM NEO, a baroreceptor neuromodulation device that delivers electrical pulses to carotid‑artery baroreceptors to restore autonomic balance and improve symptoms of heart failure. The BAROSTIM NEO is approved by the FDA for heart failure, has received FDA Breakthrough Device designation, and holds CE Marking for heart failure and resistant hypertension in the EEA. CVRx intends to commercialize BAROSTIM NEO in the United States and use recent financing proceeds to expand its U.S. footprint. The company emphasizes improving patient outcomes, quality of life, and overall cardiovascular health via its therapy. CVRx is headquartered near Minneapolis, Minnesota. CVRx develops BAROSTIM NEO, a second‑generation, minimally invasive implantable system that is CE‑marked for separate indications of heart failure and resistant hypertension. BAROSTIM NEO is commercially available in over 20 countries and the company holds an HDE approval for a legacy device in hypertension responders. CVRx is completing the BeAT‑HF Phase III pivotal clinical trial to evaluate BAROSTIM NEO’s safety and effectiveness in chronic heart failure and intends to use proceeds to support that trial and expand global commercial activities. The company cites positive prior randomized HOPE4HF trial results and published data supporting improvements in symptoms, function, and reduced hospitalization days. Founded in 2001 and headquartered in Minneapolis, Minnesota, CVRx markets its device internationally while pursuing U.S. regulatory approval through the ongoing pivotal trial. The recent financings provide near-term capital to advance clinical and commercial programs. CVRx was founded in 2001 and is headquartered in Minneapolis. The company has developed the second-generation Barostim neo, an implantable system designed to treat hypertension and heart failure. Barostim neo received CE marking for the treatment of hypertension in Europe. It is under clinical evaluation for the treatment of heart failure in Europe and the United States, and under clinical evaluation for hypertension in the United States. CVRx secured a $15M debt facility from Silicon Valley Bank and intends to use the funds to continue investing in market development and the clinical activities required to deliver Barostim Therapy. CVRx is a Minneapolis, MN-based medical device company founded in 2001 that developed Barostim neo, a medical device system designed to treat hypertension and heart failure. Barostim neo received CE marking for the treatment of hypertension in Europe and is under clinical evaluation for heart failure in Europe and the United States; it is also under clinical evaluation for hypertension in the United States. The company is led by President and CEO Nadim Yared and Executive Vice President and Chief Technology Officer Robert Kieval. CVRx closed an additional $12m in Series F financing, bringing total capital raised to $42m. Backers in the round included Ysios Capital, DaVita HealthCare Partners and others, and Josep Sanfeliu of Ysios Capital joined CVRx’s board of directors in conjunction with the funding. The company plans to use the capital to advance its clinical trials and expand its international commercial activities. CVRx, founded in 2001 and based in Minneapolis, develops the Barostim neo™, an implantable system designed to treat hypertension and heart failure. Barostim neo has received CE marking for the treatment of hypertension in Europe. The device is under clinical evaluation for the treatment of heart failure in Europe and the United States, and is also under clinical evaluation for the treatment of hypertension in the United States. CVRx is led by President and CEO Nadim Yared and Executive VP and CTO Robert Kieval. The company intends to use new funding to advance its clinical trials and to expand its international commercial activities. The article does not disclose revenue or user metrics.